EMEA-002377-PIP01-18
Key facts
| Invented name |
Empliciti
|
| Active substance |
Elotuzumab
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0267/2018
|
| PIP number |
EMEA-002377-PIP01-18
|
| Pharmaceutical form(s) |
Powder for concentrate for solution for infusion
|
| Condition(s) / indication(s) |
Treatment of Multiple Myeloma
|
| Route(s) of administration |
Intravenous use
|
| Contact for public enquiries |
Bristol-Myers Squibb Pharma EEIG
E-mail: medical.information@bms.com |
| Decision type |
W: decision granting a waiver in all age groups for all conditions or indications
|